Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

1-[2-(Benzo[1,2,5]thiadiazol-5-ylamino)-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea

EU orphan designation number: EU/3/10/770   
Active ingredient: 1-[2-(Benzo[1,2,5]thiadiazol-5-ylamino)-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea
Indication: Treatment of acute myeloid leukaemia
Sponsor: Sanofi-Aventis groupe
54 rue La Botie, F-75008 Paris, France

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
22/09/2010 Centralised Orphan - Designation EMA/OD/023/10 (2010)6637 of 20/09/2010
06/11/2012 Other procedure EMA/OD/023/10